Endocrine Abstracts

Background: The clinical attitude to the treatment of Bethesda System Category III lesions has been under controversy. Our aim was to analyse three variables and to establish a possible predictive value for carcinoma in patients with AUS/FLUS nodules.Methods: Retrospective study of 671 thyroid fine-needle aspirations (FNAs) classified as AUS/FLUS between January 2012 and June 2015. Size, sex and age were analysed, using SPSS.Result...

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...

Background: Fine-needle aspiration (FNA) is an important test for triaging patients with thyroid nodules and differentiating benign from malignant disease. According to Bethesda System Classification, the rate of AUS/FLUS is between 3–6% of all FNA. The malignancy risk is of 5–15%. TSH levels might be associated to the likelihood of malignancy in thyroid nodules according to some studies. Our aim was to establish a possible correlation between TSH level and malignanc...